These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 35027218)

  • 41. A case report of a severe fluoropyrimidine-related toxicity due to an uncommon DPYD variant.
    De Falco V; Natalicchio MI; Napolitano S; Coppola N; Conzo G; Martinelli E; Zanaletti N; Vitale P; Giunta EF; Vietri MT; Vitiello PP; Ciardiello D; Marinaccio A; De Vita F; Ciardiello F; Troiani T
    Medicine (Baltimore); 2019 May; 98(21):e15759. PubMed ID: 31124962
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Individualized Dosing of Fluoropyrimidine-Based Chemotherapy to Prevent Severe Fluoropyrimidine-Related Toxicity: What Are the Options?
    Knikman JE; Gelderblom H; Beijnen JH; Cats A; Guchelaar HJ; Henricks LM
    Clin Pharmacol Ther; 2021 Mar; 109(3):591-604. PubMed ID: 33020924
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A comprehensive population-based study comparing the phenotype and genotype in a pretherapeutic screen of dihydropyrimidine dehydrogenase deficiency.
    Pallet N; Hamdane S; Garinet S; Blons H; Zaanan A; Paillaud E; Taieb J; Laprevote O; Loriot MA; Narjoz C
    Br J Cancer; 2020 Sep; 123(5):811-818. PubMed ID: 32595208
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Fluoropyrimidine Toxicity: the Hidden Secrets of DPYD.
    Manolopoulos VG; Ragia G
    Curr Drug Metab; 2024; 25(2):91-95. PubMed ID: 38504562
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Lethal Capecitabine Toxicity in Patients With Complete Dihydropyrimidine Dehydrogenase Deficiency Due to Ultra-Rare
    van Kuilenburg ABP; Pleunis-van Empel MCH; Brouwer RB; Sijben AEJ; Knapen DG; Oude Munnink TH; van Zanden JJ; Janssens-Puister J; Dobritzsch D; Meinsma R; Meijer-Jansen J; van Dooren SJM; Vijzelaar R; Pop A; Salomons GS; Maring JG; Niezen-Koning KE
    JCO Precis Oncol; 2024 May; 8():e2300599. PubMed ID: 38709992
    [TBL] [Abstract][Full Text] [Related]  

  • 46.
    de With M; Brufau G; van den Berg LA; de Man FM; Trajkovic M; Thijs MF; Castel R; Vermeer HJ; El Bouazzaoui S; van Hemel A; Matic M; Mathijssen RHJ; Bins S; van Schaik RHN
    JCO Precis Oncol; 2022 Jul; 6():e2200180. PubMed ID: 35862869
    [TBL] [Abstract][Full Text] [Related]  

  • 47. DPYD genotyping and dihydropyrimidine dehydrogenase (DPD) phenotyping in clinical oncology. A clinically focused minireview.
    Paulsen NH; Vojdeman F; Andersen SE; Bergmann TK; Ewertz M; Plomgaard P; Hansen MR; Esbech PS; Pfeiffer P; Qvortrup C; Damkier P
    Basic Clin Pharmacol Toxicol; 2022 Nov; 131(5):325-346. PubMed ID: 35997509
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Implementing DPYD*2A Genotyping in Clinical Practice: The Quebec, Canada, Experience.
    Jolivet C; Nassabein R; Soulières D; Weng X; Amireault C; Ayoub JP; Beauregard P; Blais N; Carrier C; Cloutier AS; Desnoyers A; Lemay AS; Lemay F; Loungnarath R; Jolivet J; Letendre F; Tehfé M; Vadnais C; Viens D; Aubin F
    Oncologist; 2021 Apr; 26(4):e597-e602. PubMed ID: 33274825
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The contribution of deleterious DPYD gene sequence variants to fluoropyrimidine toxicity in British cancer patients.
    Loganayagam A; Arenas-Hernandez M; Fairbanks L; Ross P; Sanderson JD; Marinaki AM
    Cancer Chemother Pharmacol; 2010 Jan; 65(2):403-6. PubMed ID: 19795123
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Phenotype- or genotype test for dihydropyrimidin dehydrogenase deficiency before treatment with a fluoropyrimidine].
    Andersen SE; Paulsen NH; Pfeiffer P; Qvortrup C; Damkier P
    Ugeskr Laeger; 2021 Feb; 183(6):. PubMed ID: 33570023
    [TBL] [Abstract][Full Text] [Related]  

  • 51. New advances in DPYD genotype and risk of severe toxicity under capecitabine.
    Etienne-Grimaldi MC; Boyer JC; Beroud C; Mbatchi L; van Kuilenburg A; Bobin-Dubigeon C; Thomas F; Chatelut E; Merlin JL; Pinguet F; Ferrand C; Meijer J; Evrard A; Llorca L; Romieu G; Follana P; Bachelot T; Chaigneau L; Pivot X; Dieras V; Largillier R; Mousseau M; Goncalves A; Roché H; Bonneterre J; Servent V; Dohollou N; Château Y; Chamorey E; Desvignes JP; Salgado D; Ferrero JM; Milano G
    PLoS One; 2017; 12(5):e0175998. PubMed ID: 28481884
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Near Miss or Standard of Care?
    Winquist LE; Sanatani M; Kim RB; Winquist E
    Curr Oncol; 2020 Dec; 28(1):94-97. PubMed ID: 33704179
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pharmacogenetics and Metabolism from Science to Implementation in Clinical Practice: The Example of Dihydropyrimidine Dehydrogenase.
    Del Re M; Restante G; Di Paolo A; Crucitta S; Rofi E; Danesi R
    Curr Pharm Des; 2017; 23(14):2028-2034. PubMed ID: 28128059
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Strategies for DPYD testing prior to fluoropyrimidine chemotherapy in the US.
    Tracksdorf T; Smith DM; Pearse S; Cicali EJ; Aquilante CL; Scott SA; Ho TT; Patel JN; Hicks JK; Hertz DL
    Support Care Cancer; 2024 Jul; 32(8):497. PubMed ID: 38980476
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Addressing barriers to increased adoption of DPYD genotyping at a large multisite cancer center.
    Morris SA; Moore DC; Musselwhite LW; Lopes KE; Hamilton A; Steuerwald N; Hanson SL; Larck C; Swift K; Smith M; Kadakia KC; Chai S; Hwang JJ; Patel JN
    Am J Health Syst Pharm; 2023 Sep; 80(19):1342-1349. PubMed ID: 37235983
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Lethal toxicities after capecitabine intake in a previously 5-FU-treated patient: why dose matters with dihydropryimidine dehydrogenase deficiency.
    Gbeto CC; Quaranta S; Mari R; Fanciullino R; Roche C; Nahon S; Solas C; Ouafik L; Lacarelle B; Allegre T; Ciccolini J
    Pharmacogenomics; 2019 Aug; 20(13):931-938. PubMed ID: 31486738
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Polymorphisms in MIR27A Associated with Early-Onset Toxicity in Fluoropyrimidine-Based Chemotherapy.
    Amstutz U; Offer SM; Sistonen J; Joerger M; Diasio RB; Largiadèr CR
    Clin Cancer Res; 2015 May; 21(9):2038-44. PubMed ID: 25655103
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Should DPD analysis be required prior to prescribing fluoropyrimidines?
    Yen JL; McLeod HL
    Eur J Cancer; 2007 Apr; 43(6):1011-6. PubMed ID: 17350823
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Issues and limitations of available biomarkers for fluoropyrimidine-based chemotherapy toxicity, a narrative review of the literature.
    Hodroj K; Barthelemy D; Lega JC; Grenet G; Gagnieu MC; Walter T; Guitton J; Payen-Gay L
    ESMO Open; 2021 Jun; 6(3):100125. PubMed ID: 33895696
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Design and Implementation of an Opt-Out, End-to-End, Preemptive
    Jacobson JO; Rompelman G; Chen A; Morrison-Ma S; Murray L; Ferzoco M; Bunnell C; Wagner AJ; Roberts D; Chan J; Block C; Rubinson D
    JCO Oncol Pract; 2024 Aug; 20(8):1115-1122. PubMed ID: 38608224
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.